Tell a friend
(Mandatory)
(Mandatory)
(Mandatory)
(Mandatory)

EPF Acknowledgement of financial support 2013

2013   Accounts        
Acknowledgement of Financial   Support (1)        
         
EPF wishes to thank the   following donors for their support:        
      % of total income  
Operational work programme        
European Commission (Executive   Agency for Health and Consumers)      568,488.00   44.0%  
GSK        30,000.00   2.3%  
Janssen        30,000.00   2.3%  
MSD        30,000.00   2.3%  
Novartis        30,000.00   2.3%  
Pfizer        19,250.00   1.5%  
         
Project portfolio and capacity   building programme        
Abbvie        25,000.00   1.9%  
AMGEN        35,000.00   2.7%  
Baxter World Trade        10,000.00   0.8%  
CSL Behring Biotherapies        10,000.00   0.8%  
Gilead        15,000.00   1.2%  
GSK (50.000€   advance on 2014 activities)        50,000.00   3.9%  
Hoffmann-La Roche        35,000.00   2.7%  
Laboratoires Servier (10.000€ committed in 2013 to cover 2014 activities)        20,000.00   1.5%  
Novartis (20.000€   paid in 2013 to cover 2012 activities)        50,000.00   3.9%  
Philips        10,000.00   0.8%  
Sanofi-Aventis        40,000.00   3.1%  
Sanofi-Pasteur MSD        20,000.00   1.5%  
         
The   European Patients' Academy on Therapeutic Innovation Public Private   Partnership (EUPATI)        
Innovative Medicine Initiative   (IMI JU) contribution      105,125.19   8.1%  
Industry   consortium (UCB, Amgen, Genzyme, VFA, AZ, Novonordisk,   Bayer, Merck, Janssen, GSK, Chiesi, Hoffmann, Lilly, Novartis, Esteve)        47,517.77   3.7%  
         
Note:   the income provided represents EPF's share in the consortium's contributions   to the project only.        
         
EPF   wishes to thank the European Commission for its support in 2013 in relation   to EPF's role in the following projects:        
We Care        21,723.35   1.7%  
Chain of Trust        34,559.36   2.7%  
SmartCare        18,691.73   1.4%  
         
Memberships and other income        37,706.09   2.9%  
         
Total income  1,293,061.49   100.0%  
         
Accruals and deferrals (1)      205,696.52      
         
Total income net of   adjustments  1,498,758.01      
         
(1) In accordance with generally accepted accounting   principles,  funding received in-year   is subject to accrual and deferral adjustments proportionate to the level of   resources assigned to pluriannual activities and projects. In 2013, this   method had the effect of an increase of total income by € 205.696,52.